HC Wainwright Issues Optimistic Forecast for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities research analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for Theravance Biopharma in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings per share of $0.19 for the quarter, up from their previous forecast of ($0.19). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s Q3 2026 earnings at $0.28 EPS, Q4 2026 earnings at $2.02 EPS and FY2026 earnings at $2.37 EPS.

A number of other equities research analysts also recently commented on the company. Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. B. Riley Financial reissued a “neutral” rating and set a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Finally, BTIG Research lowered their price target on shares of Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.60.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $13.58 on Friday. Theravance Biopharma has a 1 year low of $7.90 and a 1 year high of $21.03. The stock has a market cap of $688.10 million, a price-to-earnings ratio of 23.82 and a beta of 0.17. The business has a fifty day moving average of $19.06 and a 200-day moving average of $16.83.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its position in Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after acquiring an additional 54,152 shares during the period. State Street Corp grew its position in Theravance Biopharma by 4.4% in the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after purchasing an additional 45,987 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Theravance Biopharma by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock worth $17,567,000 after purchasing an additional 40,734 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Theravance Biopharma by 12.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after buying an additional 92,253 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Theravance Biopharma in the third quarter valued at about $10,611,000. 99.10% of the stock is owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.